0.95
+0.016(+1.72%)
Currency In USD
| Previous Close | 0.93 |
| Open | 0.93 |
| Day High | 0.95 |
| Day Low | 0.89 |
| 52-Week High | 4.1 |
| 52-Week Low | 0.88 |
| Volume | 63,784 |
| Average Volume | 157,770 |
| Market Cap | 3.36M |
| PE | -0.24 |
| EPS | -3.98 |
| Moving Average 50 Days | 1.87 |
| Moving Average 200 Days | 2.35 |
| Change | 0.02 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $1.12 as of September 08, 2025 at a share price of $0.945. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 5 years ago, it would be worth $11.58 as of September 08, 2025 at a share price of $0.945.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies con
GT Biopharma Reports Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 14, 2025 8:05 PM GMT
GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study;
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GlobeNewswire Inc.
Aug 11, 2025 11:00 AM GMT
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 res